Instil Bio said its subsidiary has discontinued clinical development of AXN-2510 and terminated its collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) for AXN-2510 and AXN-27M.

Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Intelligent Bio Solutions stock rises after announcing a manufacturing partnership targeting over 40% cost savings, major ...

Canaccord lowered the firm’s price target on Adicet Bio (ACET) to $18 from $128 and keeps a Buy rating on the shares. The firm adjusted its price ...

Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial ...